Wall Street Zen Downgrades Oculis (NASDAQ:OCS) to Sell

Oculis (NASDAQ:OCS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other research firms also recently issued reports on OCS. Lifesci Capital began coverage on shares of Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective for the company. Needham & Company LLC lifted their price target on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. HC Wainwright increased their price target on Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Stifel Nicolaus raised their price objective on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

Oculis Stock Down 2.8%

OCS opened at $26.96 on Friday. The stock has a fifty day moving average of $26.16 and a 200-day moving average of $21.60. The company has a market capitalization of $1.56 billion, a P/E ratio of -11.88 and a beta of 0.29. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $30.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. On average, equities analysts expect that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares in the last quarter. Marshall Wace LLP acquired a new position in Oculis during the second quarter valued at approximately $393,000. Bosun Asset Management LLC acquired a new position in Oculis during the second quarter valued at approximately $378,000. Bank of America Corp DE lifted its stake in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the last quarter. Finally, Woodline Partners LP lifted its stake in Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Company is actively presenting at multiple investor conferences in March and reiterated late‑stage pipeline milestones — Privosegtor received breakthrough therapy designation (optic neuritis), OCS‑01 topline readout expected in Q2 2026, and Licaminlimab advancing as a genotype‑driven program — supporting longer‑term upside for the stock. Oculis to Participate in Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised a price target to $44 (published by AmericanBankingNews), which can provide technical/psychological support despite other model reductions. HC Wainwright Boosts Oculis Price Target
• Neutral Sentiment: Oculis filed its audited 2025 consolidated financial statements and MD&A on Form 20‑F — useful for diligence but largely informational unless the filings reveal unexpected surprises. Oculis Publishes 2025 Consolidated Financial Statements
• Neutral Sentiment: Company published notifications that RSUs granted to directors have vested and been settled — standard disclosure; could be neutral if shares are retained, or slightly negative if it leads to insider selling. Oculis Publishes Notifications of Transactions
• Negative Sentiment: Multiple analyst teams (LifeSci Capital and HC Wainwright) cut near‑term quarterly and FY2026 EPS forecasts, trimming expectations for Q1–Q4 and lowering FY numbers — these downward revisions increase near‑term earnings uncertainty and likely triggered selling pressure. (Analyst notes summarized on MarketBeat.) Analyst Estimate Reductions

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.